Reprogramming the Immune Microenvironment in Triple-Negative Breast Cancer with mRNA Therapeutics - PubMed
3 hours ago
- #tumor microenvironment
- #mRNA therapy
- #triple-negative breast cancer
- Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and HER2 expression, leading to early metastases and high recurrence rates.
- mRNA-based immunotherapies are emerging as a transformative approach in TNBC treatment, offering personalized solutions through tumor-specific antigens and immune cell engineering.
- Three principal mRNA strategies in TNBC include personalized vaccines, mRNA-engineered immune cells (CAR-T or TCR-T), and mRNA-encoded immunomodulators to reprogram the tumor microenvironment.
- Nano delivery systems are crucial for protecting mRNA, enhancing uptake, and targeting tumors or lymphoid tissues, with next-gen nanoparticles improving specificity and reducing toxicity.
- mRNA therapies hold promise for overcoming current TNBC treatment barriers, integrating precision antigen targeting, immune cell engineering, and advanced delivery technologies.